Holen Sie sich die Stockscreener-App
26.06
0.04%
0.010
Vorhandelsmarkt:
26.29
0.23
+0.88%
Schlusskurs vom Vortag:
$26.05
Offen:
$26.39
24-Stunden-Volumen:
1.15M
Relative Volume:
0.94
Marktkapitalisierung:
$3.27B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-353.00M
KGV:
-7.8963
EPS:
-3.3003
Netto-Cashflow:
$-484.00M
1W Leistung:
+5.08%
1M Leistung:
+13.50%
6M Leistung:
+31.95%
1J Leistung:
+191.50%
1-Tages-Spanne:
$25.25
$26.70
1-Wochen-Bereich:
$23.91
$26.70
52-Wochen-Spanne:
$7.06
$28.72
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
26.06 | 3.27B | 247.00M | -353.00M | -484.00M | -3.3003 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead Shift - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
Arcus (RCUS) Q1 2026 Earnings Call Transcript - AOL.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: Arcus Biosciences Q1 2026 results miss expectations - Investing.com
Arcus Biosciences Q1 Loss Narrows, Revenue Falls - marketscreener.com
Earnings Flash (RCUS) Arcus Biosciences Posts Q1 EPS -$1.02, vs. FactSet Est of -$0.88 - marketscreener.com
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q1 Revenue $17.0M, vs. FactSet Est of $29.5M - marketscreener.com
Arcus Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Arcus Biosciences (RCUS) Q1 2026 loss widens amid Gilead shift and trial setback - Stock Titan
Arcus Biosciences (NYSE: RCUS) details Q1 loss, cash runway and trial shifts - Stock Titan
Arcus lines up 2026 kidney cancer trial milestones with $876M cash - Stock Titan
MSN Money - MSN
Arcus Biosciences in the spotlight: Earnings test casdatifan focus By Investing.com - Investing.com South Africa
Arcus Biosciences Inc (RCUS) Q1 2026: Everything You Need To Kno - GuruFocus
Understanding Momentum Shifts in (RCUS) - Stock Traders Daily
Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)? - Sahm
Arcus Advances Quemliclustat With Completed Phase 1 Metabolism Study - TipRanks
What's going on with Arcus Biosciences stock on Wednesday? - MSN
Assessing Arcus Biosciences (RCUS) Valuation After STAR-121 Termination And Gilead Option Changes - Sahm
Arcus Biosciences, Inc. (RCUS) may report negative earnings: Know the trend ahead of next week's release - MSN
Arcus Biosciences (RCUS) to Release Quarterly Earnings on Tuesday - MarketBeat
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Arcus halts Gilead-partnered late-stage trial for lung cancer drug - MSN
Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now - Seeking Alpha
Arcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option Shift - Yahoo Finance
New Arcus hire gets 4,200 options and 2,100 RSUs under plan - Stock Titan
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences (RCUS) moves 7.8% higher: Will this strength last? - MSN
RCUS insider files Form 144; plans to sell 53,826 shares (NYSE: RCUS) - Stock Titan
Arcus Biosciences stock hits 52-week high at 26.5 USD By Investing.com - Investing.com India
Arcus Biosciences (NYSE:RCUS) Hits New 1-Year HighShould You Buy? - MarketBeat
Avoiding Lag: Real-Time Signals in (RCUS) Movement - Stock Traders Daily
What's Going On With Arcus Biosciences Stock On Wednesday? - Benzinga
Arcus Biosciences (RCUS) Sees 12.2% Surge in Stock Price - GuruFocus
Arcus Biosciences stock hits 52-week high at 26.5 USD - Investing.com
Arcus Biosciences (NYSE:RCUS) Trading Up 12.7%Here's Why - MarketBeat
Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last? - Yahoo Finance
[ARS] Arcus Biosciences, Inc. SEC Filing - Stock Titan
Arcus Biosciences : to Host Conference Call to Discuss First-Quarter 2026 Financia... - marketscreener.com
Cancer drug developer Arcus sets May 5 webcast on Q1 results - Stock Titan
Arcus Biosciences (NYSE: RCUS) details 2026 virtual shareholder meeting votes - Stock Titan
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):